Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History CTSO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics CTSO

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Cytosorbents Crp

CTSO
Current price
1.03 USD +0.02 USD (+1.98%)
Last closed 1.04 USD
ISIN US23283X2062
Sector Healthcare
Industry Medical Devices
Exchange NASDAQ
Capitalization 65 114 812 USD
Yield for 12 month -1.90 %
1Y
3Y
5Y
10Y
15Y
CTSO
21.11.2021 - 28.11.2021

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. The company's flagship product is CytoSorb, an extracorporeal blood purification cartridge for the treatment of massive inflammation, organ failure, cardiothoracic surgery to remove antithrombotic drugs and inflammatory mediators that can lead to postoperative complications, such as severe bleeding, shock, failure to wean from mechanical ventilation, sepsis, and multiple organ failure; DrugSorb-ATR, an antithrombotic removal system; VetResQ, a broad-spectrum blood purification adsorber for the treatment of septic shock, toxic shock syndrome, toxin-mediated diseases, pancreatitis, trauma, liver failure, heat stroke, and lung injury in animals; PuriFi, an advanced hemoperfusion pump for blood purification therapies; and ECOS-300CY, an ex vivo organ perfusion system to preserve or improve the health and quality of harvested solid organs to be transplanted. In addition, it develops HemoDefend-BGA, a blood purification technology platform to reduce anti-A and anti-B antibodies in plasma and whole blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey. Address: 305 College Road East, Princeton, NJ, United States, 08540

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

5.00 USD

P/E Ratio

Dividend Yield

Financials CTSO

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures CTSO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+35 594 520 USD

Last Year

+36 349 379 USD

Current Quarter

+8 727 000 USD

Last Quarter

+6 523 000 USD

Current Year

+25 125 991 USD

Last Year

+21 953 237 USD

Current Quarter

+6 208 000 USD

Last Quarter

+6 771 000 USD
EBITDA -14 475 458 USD
Operating Margin TTM -44.54 %
Price to Earnings
Return On Assets TTM -20.46 %
PEG Ratio
Return On Equity TTM -96.26 %
Wall Street Target Price 5.00 USD
Revenue TTM 35 332 240 USD
Book Value 0.23 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -2.90 %
Dividend Yield
Gross Profit TTM 24 459 978 USD
Earnings per share -0.29 USD
Diluted Eps TTM -0.29 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin -45.59 %

Stock Valuation CTSO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 7.73
Enterprise Value Revenue 2.30
Price Sales TTM 1.84
Enterprise Value EBITDA -1.92
Price Book MRQ 4.52

Technical Indicators CTSO

For 52 Weeks

0.71 USD 1.61 USD
50 Day MA 1.01 USD
Shares Short Prior Month 1 433 439
200 Day MA 1.03 USD
Short Ratio 16.43
Shares Short 1 481 862
Short Percent 2.48 %